BCTXF News and Press, BriaCell Therapeutics From 03/04/19

Proprietary targeted immunotherapy technology personalized to match unmet needs of advanced breast cancer patients Ongoing clinical studies of lead candidate, Bria-IMT, continue to show robust biological activity, excellent safety profile Breast cancer is one of the most commonly diagno...

BriaCell Therapeutics (OTCQB: BCTXF) (TSX.V: BCT), a biotechnology company developing targeted, safe treatments for cancer, this morning announced a non-brokered private placement financing of 5,000,000 of its common shares, each at a price of C$0.10, for gross proceeds of C$500,000. According...

BERKELEY, Calif. and VANCOUVER, British Columbia, Feb. 26, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to annou...

BriaCell Therapeutics Corp. will reveal important information about Bria-IMT and Bria-OTS at two leading conferences – the ASCO-SITC Clinical Immuno-Oncology Symposium and the American Association of Cancer Research’s annual meeting New information will also be made availabl...

Developing Bria-OTS, the first off-the-shelf personalized immunotherapy for advanced breast cancer Initiated FDA-approved phase IIa combination study of BRIA-IMT with Merck & Co. Inc.’s KEYTRUDA Impressive results in two proof-of-concept clinical trials reveal rapid response ...

New insights into BriaDX™, BriaCell’s simple patient HLA-type identification test, will be presented at 2019 ASCO-SITC Clinical Immuno-Oncology Symposium held in in San Francisco, California, February 28-March 2, 2019. Dr. Charles L. Wiseman will be a keynote speaker ...

On February 12, 2019 Jamieson Bondarenko, a recently appointed member of BriaCell Therapeutics’ (OTCQB: BCTXF) (TSX.V: BCT) Board of Directors, acquired 2,000,000 common shares of the company through the facilities of the TSX Venture Exchange at a price of $0.0975 per share for a total ...

BriaCell Therapeutics (OTCQB: BCTXF) (TSX.V: BCT), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, this morning announced the appointment of Jamieson Bondarenko, CFA, CMT, to the company's Board of Directors. Through his merchant capital c...

BERKELEY, Calif. and VANCOUVER, British Columbia, Feb. 12, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (TSX-V:BCT) (OTCQB:BCTXF) (" BriaCell " or the " Company "), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, today announces...

Multiple breakthroughs in the field of onco-immunology are expected over the next 20 years BriaCell Therapeutics Corp. is a frontrunner in this area, as it has already established proof of concept for its Bria-IMT solution for advanced breast cancer patients The company is also developi...